Pasithea Therapeutics Corp. (KTTA): Price and Financial Metrics

Pasithea Therapeutics Corp. (KTTA): $7.25

0.10 (+1.40%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Add KTTA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#356 of 387

in industry

KTTA Price/Volume Stats

Current price $7.25 52-week high $17.40
Prev. close $7.15 52-week low $5.25
Day low $7.25 Volume 1,731
Day high $7.25 Avg. volume 11,323
50-day MA $7.04 Dividend yield N/A
200-day MA $8.56 Market Cap 7.55M

KTTA Stock Price Chart Interactive Chart >

KTTA Stock Summary

  • With a price/sales ratio of 657.87, PASITHEA THERAPEUTICS CORP has a higher such ratio than 99.13% of stocks in our set.
  • With a year-over-year growth in debt of -60.78%, PASITHEA THERAPEUTICS CORP's debt growth rate surpasses merely 3.72% of about US stocks.
  • In terms of volatility of its share price, KTTA is more volatile than 99.78% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PASITHEA THERAPEUTICS CORP are KOPN, AYRO, NEON, INM, and HCWB.
  • To dig deeper into the stock's financial statements, go to KTTA's page on browse-edgar?action=getcompany&CIK=0001841330.

KTTA Valuation Summary

  • In comparison to the median Healthcare stock, KTTA's EV/EBIT ratio is 95.21% lower, now standing at 0.7.
  • KTTA's EV/EBIT ratio has moved up 954.4 over the prior 28 months.

Below are key valuation metrics over time for KTTA.

Stock Date P/S P/B P/E EV/EBIT
KTTA 2023-12-29 32.0 0.3 -0.5 0.7
KTTA 2023-12-28 33.6 0.3 -0.5 0.7
KTTA 2023-12-27 35.3 0.3 -0.5 0.7
KTTA 2023-12-26 37.3 0.3 -0.6 0.6
KTTA 2023-12-22 34.4 0.3 -0.5 0.7
KTTA 2023-12-21 24.9 0.2 -0.4 0.8

Pasithea Therapeutics Corp. (KTTA) Company Bio


Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.


KTTA Latest News Stream


Event/Time News Detail
Loading, please wait...

KTTA Latest Social Stream


Loading social stream, please wait...

View Full KTTA Social Stream

Latest KTTA News From Around the Web

Below are the latest news stories about PASITHEA THERAPEUTICS CORP that investors may wish to consider to help them evaluate KTTA as an investment opportunity.

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA) today announced that its meeting of stockholders, which had been partially adjourned on December 19, 2023, was reconvened on December 28, 2023 (the “Meeting”) and then was further adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the charter amendment proposals included as Proposals 4,

Yahoo | December 28, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

-- Solicitation Continues for Certain Charter Amendment Proposals –SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 19, 2023. Over 70% of the Company’s shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast “for” the election of directors (Proposal 1), an

Yahoo | December 19, 2023

PLTR Stock: Palantir Renews UniCredit Partnership

Palantir Technologies stock is slipping on Wednesday even with positive news for PLTR investors in the form of a renewed contract.

William White on InvestorPlace | December 13, 2023

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With ‘Overweight’ Rating

Roblox stock is rising higher on Wednesday after Wells Fargo initiated coverage of RBLX shares wit a bullish rating and price target.

William White on InvestorPlace | December 13, 2023

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

Pasithea Therapeutics stock is falling on Wednesday after shares of KTTA underwent extreme volatility yesterday on study results.

William White on InvestorPlace | December 13, 2023

Read More 'KTTA' Stories Here

KTTA Price Returns

1-mo -0.68%
3-mo -2.03%
6-mo -24.43%
1-year -3.31%
3-year N/A
5-year N/A
YTD -2.03%
2023 -42.34%
2022 -63.75%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!